NCT03767075View on ClinicalTrials.gov

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

PHASE2RecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

May 31, 2025

Study Completion Date

November 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

Atezolizumab

1200 mg, administered IV, once every 3 weeks

DRUG

Futibatinib

20 mg administered orally, once daily (QD) continuously in 28-day cycles.

DRUG

Amivantamab

1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)

Trial Locations (8)

1066

RECRUITING

Nederland Kanker Instituut (NKI), Amsterdam

17176

RECRUITING

Karolinska University Hospital Solna, Stockholm

20133

RECRUITING

Instituto Nazionale dei Tumori di Milano, Milan

69120

RECRUITING

Deutsches Krebsforschungszentrum (NCT/DKFZ), Heidelberg

94800

RECRUITING

Institut Gustave Roussy, Villejuif

01307

RECRUITING

Universitätsklinikum Dresden, Dresden

08035

RECRUITING

Hospital Vall d'Hebron, Barcelona

CB2 0QQ

RECRUITING

Cancer Research UK Cambridge Centre, Cambridge

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Iqvia Pty Ltd

INDUSTRY

collaborator

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

Janssen, LP

INDUSTRY

lead

Vall d'Hebron Institute of Oncology

OTHER

NCT03767075 - A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | Biotech Hunter | Biotech Hunter